Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells

References

• Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer 2014; 33:381-7. PMID:25096544
   PubMed Web of Science ®Google Scholar
• Sun R, Wang X, Li X. Correlation Analysis of Nasopharyngeal Carcinoma TNM Staging with Serum EA IgA and VCA IgA in EBV and VEGF–C and –D. Med Sci Monit 2015; 21:2105-9. doi:10.12659/MSM.893415. PMID:26191775
   PubMed Web of Science ®Google Scholar
• Wu EL, Riley CA, Hsieh MC, Marino MJ, Wu XC, McCoul ED. Chronic sinonasal tract inflammation as a precursor to nasopharyngeal carcinoma and sinonasal malignancy in the United States. Int Forum Allergy Rhinol 2017. doi:10.1002/alr.21956
   Google Scholar
• Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041-54. doi:10.1016/S0140-6736(05)66698-6. PMID:15950718
   PubMed Web of Science ®Google Scholar
• Feng FT, Cui Q, Liu WS, Guo YM, Feng QS, Chen LZ, Xu M, Luo B, Li DJ, Hu LF, et al. A single nucleotide polymorphism in the Epstein–Barr virus genome is strongly associated with a high risk of nasopharyngeal carcinoma. Chin J Cancer 2015; 34:563-72. doi:10.1186/s40880-015-0073-z. PMID:26675171
   PubMed Web of Science ®Google Scholar
• Liu Z, Chang ET, Liu Q, Cai Y, Zhang Z, Chen G, Huang QH, Xie SH, Cao SM, Shao JY, et al. Quantification of familial risk of nasopharyngeal carcinoma in a high–incidence area. Cancer 2017; 123(14):2716-2725. doi:10.1002/cncr.30643. PMID:28241094
   PubMed Web of Science ®Google Scholar
• Wang C, Lin XL, Fan YY, Liu YT, Zhang XL, Lu YK, Xu CH, Chen YM. Diet quality scores and risk of Nasopharyngeal Carcinoma in Chinese adults: a case–control study. Nutrients 2016; 8:112. doi:10.3390/nu8030112. PMID:26927167
   PubMed Web of Science ®Google Scholar
• Lin JH, Jiang CQ, Ho SY, Zhang WS, Mai ZM, Xu L, Lo CM, Lam TH. Smoking and nasopharyngeal carcinoma mortality: a cohort study of 101,823 adults in Guangzhou, China. BMC Cancer 2015; 15:906. doi:10.1186/s12885-015-1902-9. PMID:26573573
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17:1509-20. doi:10.1016/S1470-2045(16)30410-7. PMID:27686945
   PubMed Web of Science ®Google Scholar
• Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Prognostic value of multidrug resistance 1, glutathione–S–transferase–pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology 2002; 62:305-12. doi:10.1159/000065061. PMID:12138237
   PubMed Web of Science ®Google Scholar
• Wang X, Masters JR, Wong YC, Lo AK, Tsao SW. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Res 2001; 21:403-8. PMID:11299769
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9:265-73. doi:10.1038/nrc2620. PMID:19262571
   PubMed Web of Science ®Google Scholar
• Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial–mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology 2012; 79:195-208. doi:10.1159/000337106. PMID:22488297
   PubMed Web of Science ®Google Scholar
• Samatov TR, Tonevitsky AG, Schumacher U. Epithelial–mesenchymal transition: focus on metastatic cascade, alternative splicing, non–coding RNAs and modulating compounds. Mol Cancer 2013; 12:107. doi:10.1186/1476-4598-12-107. PMID:24053443
   PubMed Web of Science ®Google Scholar
• Luo WR, Chen XY, Li SY, Wu AB, Yao KT. Neoplastic spindle cells in nasopharyngeal carcinoma show features of epithelial–mesenchymal transition. Histopathology 2012; 61:113-22. doi:10.1111/j.1365-2559.2012.04205.x. PMID:22486228
   PubMed Web of Science ®Google Scholar
• Jiang H, Gao M, Shen Z, Luo B, Li R, Jiang X, Ding R, Ha Y, Wang Z, Jie W. Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal–epithelial reverting transition. Oncol Rep 2014; 32:559-66. PMID:24889918
   PubMed Web of Science ®Google Scholar
• Wu Y, Shen Z, Wang K, Ha Y, Lei H, Jia Y, Ding R, Wu D, Gan S, Li R, et al. High FMNL3 expression promotes nasopharyngeal carcinoma cell metastasis: role in TGF–beta1–induced epithelia–to–mesenchymal transition. Sci Rep 2017; 7:42507. doi:10.1038/srep42507. PMID:28198387
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B, Liu Y, Liu Y, Yin L, Peng Y, et al. The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis 2017; 8:e2659. doi:10.1038/cddis.2017.53. PMID:28277541
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ Size control, tissue homeostasis, and cancer. Cell 2015; 163:811-28. doi:10.1016/j.cell.2015.10.044. PMID:26544935
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13:246-57. doi:10.1038/nrc3458. PMID:23467301
   PubMed Web of Science ®Google Scholar
• Deng J, Lei W, Xiang X, Zhang L, Lei J, Gong Y, Song M, Wang Y, Fang Z, Yu F, et al. Cullin 4A (CUL4A), a direct target of miR–9 and miR–137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway. Oncotarget 2016; 7:10037-50. PMID:26840256
   PubMed Web of Science ®Google Scholar
• Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 2013; 19:4925-30. doi:10.1158/1078-0432.CCR-12-3172. PMID:23797907
   PubMed Web of Science ®Google Scholar
• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13:63-79. doi:10.1038/nrd4161. PMID:24336504
   PubMed Web of Science ®Google Scholar
• Li W, Dong S, Wei W, Wang G, Zhang A, Pu P, Jia Z. The role of transcriptional coactivator TAZ in gliomas. Oncotarget 2016; 7:82686-99. PMID:27764783
   PubMed Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell 2016; 29:783-803. doi:10.1016/j.ccell.2016.05.005. PMID:27300434
   PubMed Web of Science ®Google Scholar
• Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell AD, Jr, Sudol M, Passaniti A. RUNX2 and TAZ–dependent signaling pathways regulate soluble E–Cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget 2015; 6:28132-50. doi:10.18632/oncotarget.4654. PMID:26320173
   PubMed Web of Science ®Google Scholar
• Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al. The Hippo transducer TAZ confers cancer stem cell–related traits on breast cancer cells. Cell 2011; 147:759-72. doi:10.1016/j.cell.2011.09.048. PMID:22078877
   PubMed Web of Science ®Google Scholar
• Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25:2594-609. doi:10.1101/gad.176800.111. PMID:22190458
   PubMed Web of Science ®Google Scholar
• Chen G, Xie J, Huang P, Yang Z. Overexpression of TAZ promotes cell proliferation, migration and epithelial–mesenchymal transition in ovarian cancer. Oncol Lett 2016; 12:1821-5. PMID:27588129
   PubMed Web of Science ®Google Scholar
• Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, Zhao S, Xiong Y, Guan KL. TAZ promotes cell proliferation and epithelial–mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28:2426-36. doi:10.1128/MCB.01874-07. PMID:18227151
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial–mesenchymal transition. J Biol Chem 2009; 284:13355-62. doi:10.1074/jbc.M900843200. PMID:19324877
   PubMed Web of Science ®Google Scholar
• Xie D, Cui J, Xia T, Jia Z, Wang L, Wei W, Zhu A, Gao Y, Xie K, Quan M. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Oncotarget 2015; 6:35949-63. PMID:26416426
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, Qi B, Qiu J, Song X, Ye J, et al. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol 2015; 9:1091-105. doi:10.1016/j.molonc.2015.01.007. PMID:25704916
   PubMed Web of Science ®Google Scholar
• Xiao H, Jiang N, Zhou B, Liu Q, Du C. TAZ regulates cell proliferation and epithelial–mesenchymal transition of human hepatocellular carcinoma. Cancer Sci 2015; 106:151-9. doi:10.1111/cas.12587. PMID:25495189
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu Z, An Q, Jiang D, Wang L, Liang B, Li Z. TAZ promotes epithelial to mesenchymal transition via the upregulation of connective tissue growth factor expression in neuroblastoma cells. Mol Med Rep 2015; 11:982-8. PMID:25354978
   PubMed Web of Science ®Google Scholar
• Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71:2728-38. doi:10.1158/0008-5472.CAN-10-2711. PMID:21349946
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang S, Wang Z, Feng X, Liu P, Lv XB, Li F, Yu FX, Sun Y, Yuan H, et al. Estrogen regulates Hippo signaling via GPER in breast cancer. J Clin Invest 2015; 125:2123-35. doi:10.1172/JCI79573. PMID:25893606
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Ueda Y, Hirono Y, Goi T, Yamaguchi A. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo–YAP pathway. Oncotarget 2015; 6:34788-99. PMID:26431277
   PubMed Web of Science ®Google Scholar
• Chan JW, Parvathaneni U, Yom SS. Reducing radiation–related morbidity in the treatment of nasopharyngeal carcinoma. Future Oncol 2017; 13:425-31. doi:10.2217/fon-2016-0410. PMID:27875901
   PubMed Web of Science ®Google Scholar
• Townsend DM, Tew KD, He L, King JB, Hanigan MH. Role of glutathione S–transferase Pi in cisplatin–induced nephrotoxicity. Biomed Pharmacother 2009; 63:79-85. doi:10.1016/j.biopha.2008.08.004. PMID:18819770
   PubMed Web of Science ®Google Scholar
• Dugbartey GJ, Peppone LJ, de Graaf IA. An integrative view of cisplatin–induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 2016; 371:58-66. doi:10.1016/j.tox.2016.10.001. PMID:27717837
   PubMed Web of Science ®Google Scholar
• Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self–defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012; 64:706-21. doi:10.1124/pr.111.005637. PMID:22659329
   PubMed Web of Science ®Google Scholar
• Matteucci E, Maroni P, Luzzati A, Perrucchini G, Bendinelli P, Desiderio MA. Bone metastatic process of breast cancer involves methylation state affecting E–cadherin expression through TAZ and WWOX nuclear effectors. Eur J Cancer 2013; 49:231-44. doi:10.1016/j.ejca.2012.05.006. PMID:22717556
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96. doi:10.1038/nrm3758. PMID:24556840
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine–resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69:2400-7. doi:10.1158/0008-5472.CAN-08-4312. PMID:19276344
   PubMed Web of Science ®Google Scholar
• Wu Q, Wang R, Yang Q, Hou X, Chen S, Hou Y, Chen C, Yang Y, Miele L, Sarkar FH, et al. Chemoresistance to gemcitabine in hepatoma cells induces epithelial–mesenchymal transition and involves activation of PDGF–D pathway. Oncotarget 2013; 4:1999-2009. doi:10.18632/oncotarget.1471. PMID:24158561
   PubMed Web of Science ®Google Scholar
• Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, Chen S, Chen C, Wang Z. Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel–resistant breast cancer cells. Br J Cancer 2014; 110:1958-67. doi:10.1038/bjc.2014.136. PMID:24642627
   PubMed Web of Science ®Google Scholar
• Chen DJ, Chen W, Jiang H, Yang H, Wang YC, Chen JH. Downregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial–mesenchymal transition. Drug Des Devel Ther 2016; 10:2845-53. doi:10.2147/DDDT.S101998. PMID:27660415
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu H, Xia F, Zhang QW, Zhang YY, Zhao Q, Chao ZH, Jiang ZW, Jiang CC. Epithelial–mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int J Mol Med 2014; 33:151-9. PMID:24173500
   PubMed Web of Science ®Google Scholar
• Zhou X, Lei QY. Regulation of TAZ in cancer. Protein Cell 2016; 7:548-61. doi:10.1007/s13238-016-0288-z. PMID:27412635
   PubMed Web of Science ®Google Scholar
• Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2015; 34:681-90. doi:10.1038/onc.2014.5. PMID:24531710
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang X. Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1–TAZ signalling. Oncotarget 2015; 6:21906-17. doi:10.18632/oncotarget.4259. PMID:26183396
   PubMed Web of Science ®Google Scholar
• Tian T, Li A, Lu H, Luo R, Zhang M, Li Z. TAZ promotes temozolomide resistance by upregulating MCL–1 in human glioma cells. Biochem Biophys Res Commun 2015; 463:638-43. doi:10.1016/j.bbrc.2015.05.115. PMID:26043698
   PubMed Web of Science ®Google Scholar
• Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X, Wang Z, Yang Y, Chen C, Wu Q. The PDGF–D/miR–106a/Twist1 pathway orchestrates epithelial–mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget 2015; 6:7000-10. doi:10.18632/oncotarget.3193. PMID:25760076
   PubMed Web of Science ®Google Scholar
• Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X, Chen S, Chen C, Wang Z. Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel–resistant breast cancer cells. Br J Cancer 2014; 110:1958-67. doi:10.1038/bjc.2014.136. PMID:24642627
   PubMed Web of Science ®Google Scholar
• Wang L, Ye X, Cai X, Su J, Ma R, Yin X, Zhou X, Li H, Wang Z. Curcumin suppresses cell growth and invasion and induces apoptosis by down–regulation of Skp2 pathway in glioma cells. Oncotarget 2015; 6:18027-37. doi:10.18632/oncotarget.4090. PMID:26046466
   PubMed Web of Science ®Google Scholar
• Zhou X, Su J, Feng S, Wang L, Yin X, Yan J, Wang Z. Antitumor activity of curcumin is involved in down–regulation of YAP/TAZ expression in pancreatic cancer cells. Oncotarget 2016; 7:79076-88. PMID:27738325
   PubMedGoogle Scholar
• Ma J, Zeng F, Ma C, Pang H, Fang B, Lian C, Yin B, Zhang X, Wang Z, Xia J. Synergistic reversal effect of epithelial–to–mesenchymal transition by miR–223 inhibitor and genistein in gemcitabine–resistant pancreatic cancer cells. Am J Cancer Res 2016; 6:1384-95. PMID:27429851
   PubMed Web of Science ®Google Scholar
• Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen S, Wu Q, Chen C, Wang Z. MiR–125b regulates epithelial–mesenchymal transition via targeting Sema4C in paclitaxel–resistant breast cancer cells. Oncotarget 2015; 6:3268-79. doi:10.18632/oncotarget.3065. PMID:25605244
   PubMed Web of Science ®Google Scholar
• Wang L, Hou Y, Yin X, Su J, Zhao Z, Ye X, Zhou X, Zhou L, Wang Z. Rottlerin inhibits cell growth and invasion via down–regulation of Cdc20 in glioma cells. Oncotarget 2016; 7:69770-82. PMID:27626499
   PubMed Web of Science ®Google Scholar